Did Prosensa hurt IPO chances by disclosing Sarepta risk?
This article was originally published in Scrip
Executive Summary
Prosensa may have set itself up for a difficult initial public offering, despite the recent rise of the US biotechnology IPO market, by noting that a competing Duchenne muscular dystrophy (DMD) drug may be better than its own RNA-modulating therapy drisapersen.